Bitopertin R enantiomer

• CAT Number: I005057
• CAS Number: 845614-12-2
• Molecular Formula: C21H20F7N3O4S
• Molecular Weight: 543.46
• Purity: ≥95%
• Synonyms: [4-[3-fluoro-5-(trifluoromethyl)pyridin-2-yl]piperazin-1-yl]-[5-methylsulfonyl-2-[(2R)-1,1,1-trifluoropropan-2-yl]oxyphenyl]methanone
• Target: Neuronal Signaling
• Solubility: 10 mM in DMSO
• Storage: Store at -20°C
• IUPAC Name: [4-[3-fluoro-5-(trifluoromethyl)pyridin-2-yl]piperazin-1-yl]-[5-methylsulfonyl-2-(1,1,1-trifluoropropan-2-yloxy)phenyl]methanone
• InChI: InChI=1S/C21H20F7N3O4S/c1-12(20(23,24)25)35-17-4-3-14(36(2,33)34)10-15(17)19(32)31-7-5-30(6-8-31)18-16(22)9-13(11-29-18)21(26,27)28/h3-4,9-12H,5-8H2,1-2H3
• InChIKey: YUUGYIUSCYNSQR-UHFFFAOYSA-N
• SMILES: CC(C(F)(F)F)OC1=C(C=C(C=C1)S(=O)(=O)C)C(=O)N2CCN(CC2)C3=C(C=C(C=N3)C(F)(F)F)F

Bitopertin R-Enantiomer(CAT: I005057) is a selective glycine transporter type 1 (GlyT1) inhibitor, extensively studied in neuroscience and psychiatric research. By modulating glycine levels at the synaptic cleft, it enhances NMDA receptor function, making it valuable in exploring the pathophysiology of schizophrenia and other cognitive disorders. The R-enantiomer offers high selectivity and potency, enabling detailed investigation of enantiomer-specific activity and pharmacodynamics. Bitopertin R-Enantiomer is a critical tool for studying the role of glycine transporters in neurotransmission and for advancing the development of novel therapeutics targeting neurological and psychiatric conditions.

Reference

[1]. Pinard, Emmanuel; Alanine, Alexander; Alberati, Daniela et al. Selective GlyT1 Inhibitors: Discovery of [4-(3-Fluoro-5-trifluoromethylpyridin-2-yl)piperazin-1-yl][5-methanesulfonyl-2-((S)-2,2,2-trifluoro-1-methylethoxy)phenyl]methanone (RG1678), a Promising Novel Medicine To Treat Schizophrenia. Journal of Medicinal Chemistry (2010), 53(12), 4603-4614.
[2]. Hopkins, Corey R. ACS Chemical Neuroscience Molecule Spotlight on RG1678. ACS Chemical Neuroscience (2011), 2(12), 685-686.
[3]. Alberati, Daniela; Moreau, Jean-Luc; Lengyel, Judith et al. Glycine reuptake inhibitor RG1678: A pharmacologic characterization of an investigational agent for the treatment of schizophrenia. Neuropharmacology (2012), 62(2), 1152-1161.
[4]. Hofmann C, Banken L, Hahn M et al. Evaluation of the Effects of Bitopertin (RG1678) on Cardiac Repolarization: A Thorough Corrected QT Study in Healthy Male Volunteers. Clin Ther. 2012 Oct;34(10):2061-71.
[5]. Martin-Facklam M, Pizzagalli F, Zhou Y et al. Glycine Transporter Type 1 Occupancy by Bitopertin: a Positron Emission Tomography Study in Healthy Volunteers. Neuropsychopharmacology. 2012 Nov 7. doi: 10.1038/npp.2012.212. [Epub ahead of print]